semaglutide shortage november 2025 news Novo's Wegovy and Ozempic removed from US FDA list, compounders on notice The Semaglutide Shortage Is Ending:

GLP-1 therapies have been around, but the focus has intensified because of how quickly the market is growing

[DOI] [PMC free article] [PubMed] [Google Scholar] 85.Anderberg R.H., Anefors C., Bergquist F., Nissbrandt H., Skibicka K.P

In practice, the greatest risk of adverse events happens among: People taking any dose of GLP-1 when they are not clinically indicated for the medication People taking compounded GLP-1 medications or GLP-1 medications that are not approved by the FDA People self-adjusting doses without physician oversight The Lure and Limits of Microdosing GLP-1s People who experience side effects from traditional GLP-1s may turn to microdosing in hopes of alleviating discomfort associated with nausea, diarrhea and vomiting

Semaglutide is a prescription medication that mimics a naturally occurring hormone called GLP-1 (glucagon-like peptide-1), which regulates appetite and blood sugar levels.